Search
Atea Pharmaceuticals Inc
AVIRAdd to Watchlist
4.160USD
+0.120+2.97%
Close 10-26 16:00（ET）
333.63MMarket Cap
LossP/E TTM
Today
+2.97%
5 Days
-5.24%
1 Month
-19.54%
6 Months
-23.95%
Year to Date
+16.53%
1 Year
+29.60%
Key Figures
4.040Open
4.240High
36.60KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.05%Turnover Ratio
4.040Prev. Close
3.940Low
152.69KTurnover
LossP/E Static
1.63P/B
0.00%Div Yield TTM
-47.95%ROA
6.45052wk High
0.11Volume Ratio
-168.38MNet Profit
80.20MShares
-2.1143EPS TTM
0.34Beta
-52.58%ROE
2.87052wk Low
7.55%Amplitude
--Gross Margin
333.63MMarket Cap
2.27Reward/Risk
3.24%Risk Rate
Atea Pharmaceuticals Inc's Score
-0.01vs previous score
Forecast8.00
Financial Health6.09
Technical4.55
Valuation Dimensions6.32
Institutional Confidence7.00
Risk Assessment4.86
Media Coverage
Coverage Level
Very Low
Very High
Positive
Analyst Rating
Atea Pharmaceuticals Inc Technical Analysis
Technical Indicators
Sell
Summary
Sell
Moving Average
Strong sell
Atea Pharmaceuticals Inc Latest Earnings Call Transcripts
Atea Pharmaceuticals (AVIR) Q2 2026 Earnings Call: C-BEYOND Meets Phase 3 Endpoint
Atea Pharmaceuticals’ Q2 2026 earnings call covered positive Phase 3 C-BEYOND HCV data, $219.5 million in cash and key 2027 regulatory milestones.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-0.41/-0.56
Revenue / Forecast
--/0.00
Atea Pharmaceuticals Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolAVIR
Number of employees56
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 12.09% |
| BML Capital Management LLC | 8.82% |
| BlackRock Institutional Trust Company, N.A. | 7.79% |
| JPM Partner LLC | 6.39% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 44.60% |
| Investment Advisor/Hedge Fund | 12.77% |
| Hedge Fund | 11.88% |
| Individual Investor | 7.00% |
Related Instruments
+0.45%
+0.94%
+0.39%
-3.21%
+1.78%
+0.33%
+1.22%
+1.70%
+0.20%
-0.80%
-1.23%
+0.21%
-0.79%
+0.69%
+0.46%
+0.33%
-0.62%
+0.94%
+0.79%
-0.50%Popular Instruments
52442.500
+110.100 (+0.21%)
29169.200
-131.900 (-0.45%)
7673.400
-3.700 (-0.05%)
13016.000
-24.000 (-0.18%)
63236.000
+457.000 (+0.73%)
6094.300
-1.900 (-0.03%)
100.902
-0.058 (-0.06%)
343.910
-3.815 (-1.10%)
216.000
+5.040 (+2.39%)
4003.660
-12.920 (-0.32%)
FAQs
What is the current price of Atea Pharmaceuticals Inc (AVIR)?
The current price of Atea Pharmaceuticals Inc (AVIR) is 4.16.
What is the symbol of Atea Pharmaceuticals Inc?
The ticker symbol of Atea Pharmaceuticals Inc is AVIR.
What is the 52-week high of Atea Pharmaceuticals Inc?
The 52-week high of Atea Pharmaceuticals Inc is 6.45.
What is the 52-week low of Atea Pharmaceuticals Inc?
The 52-week low of Atea Pharmaceuticals Inc is 2.87.
What is the market capitalization of Atea Pharmaceuticals Inc?
The market capitalization of Atea Pharmaceuticals Inc is 333.63M.
Is Atea Pharmaceuticals Inc (AVIR) currently rated as Buy, Hold, or Sell?
According to analysts, Atea Pharmaceuticals Inc (AVIR) has an overall rating of Buy, with a price target of 8.50.
What is the Earnings Per Share (EPS TTM) of Atea Pharmaceuticals Inc (AVIR)?
The Earnings Per Share (EPS TTM) of Atea Pharmaceuticals Inc (AVIR) is -2.11.